
HeartFlow
Founded Year
2007Stage
IPO | IPOTotal Raised
$855.77MDate of IPO
8/8/2025Market Cap
2.82BStock Price
27.98Revenue
$0000About HeartFlow
HeartFlow specializes in artificial intelligence (AI)-driven management of coronary artery disease within the healthcare sector. The company provides a precision coronary care platform that utilizes technology to create personalized three-dimensional (3D) heart models from computerized tomography (CT) scans, aiding in the diagnosis and treatment of Coronary Artery Disease (CAD). HeartFlow's solutions are utilized by healthcare providers for coronary care. HeartFlow was formerly known as Cardiovascular Simulation. It was founded in 2007 and is based in Mountain View, California.
Loading...
HeartFlow's Product Videos
ESPs containing HeartFlow
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The cardiac CT analytics platforms market is focused on improving the diagnosis and management of heart disease through the use of artificial intelligence and advanced imaging technologies. Companies in this market use tech to accurately detect and analyze features such as coronary artery stenosis, ventricular hypertrophy, and other anomalies that can be indicative of cardiac-related diseases. Tec…
HeartFlow named as Outperformer among 13 other companies, including Siemens Healthineers, GE Healthcare, and Philips.
HeartFlow's Products & Differentiators
HeartFlow FFRct Analysis
The HeartFlow Analysis is a personalized cardiac test that leverages algorithms trained using deep learning and highly trained analysts to create a digital, personalized 3D model of the heart. The HeartFlow Analysis then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and provides FFRCT values along the coronary arteries. This information is used by physicians in evaluating the impact a blockage may be having on blood flow and determine the optimal course of treatment for each patient.
Loading...
Research containing HeartFlow
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned HeartFlow in 4 CB Insights research briefs, most recently on Oct 28, 2025.

Oct 28, 2025 report
State of Digital Health Q3’25 Report

Aug 1, 2023
The state of healthcare AI in 5 charts
Jul 26, 2023 report
State of Digital Health Q2’23 ReportExpert Collections containing HeartFlow
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
HeartFlow is included in 5 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,309 items
Tech IPO Pipeline
568 items
Digital Health 50
150 items
The most promising digital health startups transforming the healthcare industry
Digital Health
12,122 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Artificial Intelligence (AI)
20,894 items
HeartFlow Patents
HeartFlow has filed 384 patents.
The 3 most popular patent topics include:
- cardiology
- heart diseases
- cardiac arrhythmia

Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/6/2023 | 2/11/2025 | Medical imaging, Magnetic resonance imaging, Machine learning, Image processing, Health informatics | Grant |
Application Date | 11/6/2023 |
|---|---|
Grant Date | 2/11/2025 |
Title | |
Related Topics | Medical imaging, Magnetic resonance imaging, Machine learning, Image processing, Health informatics |
Status | Grant |
Latest HeartFlow News
Nov 13, 2025
Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, November 13, 2025 / EINPresswire.com / -- "Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors What Is The Digital Twin Cardiac Ablation Suite Market Size And Growth? The market size for the digital twin cardiac ablation suite has seen exponential growth recently, escalating from $0.80 billion in 2024 to $0.99 billion in 2025, reflecting a compound annual growth rate (CAGR) of 23.0%. This substantial growth during the historic period can be traced back to the surging demand for remote patient monitoring, increase in clinical trials pertaining to cardiac ablation, enhanced cost-efficiency of digital twin solutions, improved availability of high-resolution cardiac imaging, and a rise in government initiatives that favor advanced cardiac care. In the coming years, the market size of the digital twin cardiac ablation suite is projected to expand significantly, growing to $2.23 billion by 2029 with a compound annual growth rate (CAGR) of 22.7%. The growth during the forecasted period could be due to the cost-effective nature of digital twin solutions, enhanced training and education for healthcare professionals, increased market competition and innovation, growing integration of telemedicine, and the increased use of real-time monitoring for cardiac procedures. Key trends for this forecast period include the innovation in patient engagement platforms, increased accuracy through the integration of multi-source cardiac data, advancements in augmented reality-assisted interventions, continuous monitoring through wearable health devices integration, and improvements in high-fidelity electrophysiological simulations. Download a free sample of the digital twin cardiac ablation suite market report: https://www.thebusinessresearchcompany.com/sample.aspx?id=29030&type=smp What Are The Current Leading Growth Drivers For Digital Twin Cardiac Ablation Suite Market? The increasing incidence of cardiovascular diseases is projected to drive the expansion of the digital twin cardiac ablation suite market in the foreseeable future. Cardiovascular diseases, which involve conditions that affect the heart and blood vessels, could result in severe outcomes such as heart attacks and strokes. These diseases are becoming more common due to the aging population in developed countries, as advanced age is a major risk factor for heart-related diseases and complexities. Digital Twin Cardiac Ablation Suites aid in managing such diseases by generating virtual duplicates of the patient's heart, which allow doctors to simulate and refine ablation procedures before actual treatment. This enhances the results and minimizes risks for patients with cardiac arrhythmias. To illustrate, the Centers for Disease Control and Prevention, a US-based government agency, stated in October 2024 that 919,032 lives were claimed by cardiovascular disease, accounting for a third of all deaths. Coronary heart disease was the most common type, and remarkably, about one-sixth of cardiovascular disease deaths were individuals under the age of 65. Consequently, the mounting prevalence of cardiovascular diseases is fuelling the digital twin cardiac ablation suite market's growth. Owing to the improvements in genomic technologies, the escalating focus on precision medicine is forecasted to spur the digital twin cardiac ablation suite market's expansion. Precision medicine is a healthcare approach designed to customize treatments for patients based on their genetic profile, lifestyle, and environmental influences. There is a growing focus on precision medicine due to the evolution of genomic sequencing technologies and data analysis. These technologies allow healthcare professionals to pinpoint specific biomarkers and devise specialized therapies, enhancing patient outcomes. Digital twin cardiac ablation suites facilitate precision medicine by generating virtual models of patient's hearts, enabling doctors to simulate and adjust ablation plans suited to each patient's unique cardiac anatomy and arrhythmia patterns before actual procedures. In February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new individualized treatments for patients with rare diseases, a substantial rise from the six approvals in 2022. As such, the growing interest in precision medicine is pushing the expansion of the digital twin cardiac ablation suite market. Which Companies Are Currently Leading In The Digital Twin Cardiac Ablation Suite Market? Major players in the Digital Twin Cardiac Ablation Suite Global Market Report 2025 include: • Siemens Healthineers AG • Koninklijke Philips N.V. • GE HealthCare Technologies Inc. • Boston Scientific Corporation • Dassault Systèmes SE • Lepu Medical Technology (Beijing) Co. Ltd. • HeartFlow Inc. • AliveCor Inc. • Stereotaxis Inc. • CardioFocus Inc. How Is The Digital Twin Cardiac Ablation Suite Market Segmented The digital twin cardiac ablation suitemarket covered in this report is segmented – 1) By Component: Software, Hardware, Services 2) By Deployment Mode: On-Premises, Cloud-Based 3) By Application: Preoperative Planning, Intraoperative Guidance, Postoperative Assessment, Training And Education, Other Applications 4) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Other End-Users Subsegments: 1) By Software: Virtual Heart Modeling, Cardiac Simulation Software, Electrophysiology Simulation Tools, Patient Specific Cardiac Modeling, Three Dimensional Cardiac Mapping 2) By Hardware: Imaging Devices, Catheter Systems, Sensors And Electrodes, Computing Systems, Data Storage Devices 3) By Services: Installation And Integration Services, Maintenance And Support Services, Training And Education Services, Consulting Services, Remote Monitoring Services View the full digital twin cardiac ablation suite market report: https://www.thebusinessresearchcompany.com/report/digital-twin-cardiac-ablation-suite-global-market-report Which Is The Dominating Region For The Digital Twin Cardiac Ablation Suite Market? In the Digital Twin Cardiac Ablation Suite Global Market Report 2025, North America held the leading position in 2024. It is predicted that Asia-Pacific will be experiencing the most rapid growth during the forecast period. The report provides market analysis for the following regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Browse Through More Reports Similar to the Global Digital Twin Cardiac Ablation Suite Market 2025, By The Business Research Company Cardiovascular Digital Solutions Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/cardiovascular-digital-solutions-global-market-report Digital Twin Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/digital-twin-global-market-report Digital Twin Technology Global Market Report Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/digital-twin-technology-global-market-report Speak With Our Expert: Saumya Sahay Americas +1 310-496-7795 Asia +44 7882 955267 & +91 8897263534 Europe +44 7882 955267 Email: saumyas@tbrc.info The Business Research Company - www.thebusinessresearchcompany.com Follow Us On: • LinkedIn: https://in.linkedin.com/company/the-business-research-company Oliver Guirdham The Business Research Company info@tbrc.info Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
HeartFlow Frequently Asked Questions (FAQ)
When was HeartFlow founded?
HeartFlow was founded in 2007.
Where is HeartFlow's headquarters?
HeartFlow's headquarters is located at 331 East Evelyn Avenue, Mountain View.
What is HeartFlow's latest funding round?
HeartFlow's latest funding round is IPO.
How much did HeartFlow raise?
HeartFlow raised a total of $855.77M.
Who are the investors of HeartFlow?
Investors of HeartFlow include U.S. Venture Partners, HealthCor Management, Martis Capital, Wellington Management, Capricorn Investment Group and 19 more.
Who are HeartFlow's competitors?
Competitors of HeartFlow include Elucid, HEARTio, MEDICAL IP, Cleerly, Caristo Diagnostics and 7 more.
What products does HeartFlow offer?
HeartFlow's products include HeartFlow FFRct Analysis.
Who are HeartFlow's customers?
Customers of HeartFlow include Atrium Health.
Loading...
Compare HeartFlow to Competitors

Corcillum specializes in cardiovascular diagnostics and research within the healthcare technology sector. Its main offerings include a platform for medical image annotation, multi-physics modeling, and the development of digital coronary twins for personalized cardiovascular assessments. Corcillum serves the healthcare and medical research sectors with its solutions. It was founded in 2022 and is based in Adelaide, Australia.

Cleerly is a digital healthcare company focused on the diagnosis and treatment of heart disease through its solutions in the cardiovascular care sector. The company offers a digital care platform that uses non-invasive CT imaging to identify and quantify atherosclerosis, enabling treatment plans for heart disease. Cleerly's technology aims to provide phenotyping of coronary artery disease, improving the accuracy of heart attack risk assessments and supporting clinical decision-making. It was founded in 2017 and is based in Denver, Colorado.

Caristo Diagnostics specializes in cardiovascular diagnostic tools within the healthcare technology sector. The company enhances the accuracy of routine cardiac computed tomography scans by identifying coronary inflammation and other hidden cardiac issues, which improves the prediction of cardiovascular risk and aids in treatment decisions. Its technology is utilized in preventive screening, disease diagnosis, intervention planning, and clinical research. The company was founded in 2017 and is based in Oxford, United Kingdom.

Elucid specializes in advanced arterial analysis software within the healthcare technology sector. The company offers software that provides objective and quantitative assessment of arterial plaque, validated by histology, to aid in the diagnosis and treatment of cardiovascular diseases. Its software is designed to support physicians, patients, and clinical researchers by improving the accuracy of noninvasive testing and enabling personalized care. It was founded in 2013 and is based in Boston, Massachusetts.

Perspectum provides imaging solutions within the healthcare industry and focuses on precision medicine. The company offers diagnostic tools that extract biomarkers from medical imaging to assist in the diagnosis and treatment of conditions, including liver disease, diabetes, and cancer. Perspectum's technology aims to help healthcare providers by offering data relevant to patient care. It was founded in 2012 and is based in Oxford, United Kingdom.

Resonance Health is a MedTech company specializing in non-invasive medical imaging analysis and clinical trial services within the healthcare sector. The company offers a range of MRI-based products that provide quantitative assessments of liver and heart iron concentration, as well as automated AI-powered liver fat analysis, to aid in patient diagnosis and management. Resonance Health also provides clinical trial services, including standalone diagnostic imaging and central laboratory analysis. It was founded in 2000 and is based in Burswood, Western Australia.
Loading...